GE Aerospace continues to be rated as a 'Buy' with a target price of $402.85, indicating a potential upside of nearly 18%. This positive outlook is attributed to the company's leading position in engine programs like CFM LEAP, GEnx, and GE9X, coupled with robust aftermarket revenue streams. Despite recent geopolitical risks and supply chain concerns, GE Aerospace's diversified fleet and pricing power are expected to mitigate these challenges, maintaining its growth trajectory.

Eikon Therapeutics has been assigned a Sell rating due to substantial dilution risks associated with its impending lock-up expiry. While its lead asset, EIK1001, demonstrates encouraging early data in NSCLC and melanoma, pivotal trial results are not anticipated until 2027. The company's cash reserves are projected to last only until the second half of 2027, making additional equity financing highly probable within the next year. With insider-held shares set to unlock in August 2026 and a lack of significant near-term catalysts, further stock depreciation is expected.

The first quarter of 2026 witnessed significant shifts in global markets, driven by geopolitical tensions and their impact on commodity prices. The closure of the Strait of Hormuz disrupted crucial supply chains, leading to a hawkish repricing of interest rate expectations by central banks. Technology sectors experienced contrasting fortunes, with large cap companies exceeding capital expenditure forecasts while software firms faced challenges due to AI disruption. Amidst these changes, the U.S. Treasury yield curve flattened as short-term yields rose more sharply than long-term yields. Northern Funds Limited Term U.S. Government Fund underperformed its benchmark, primarily influenced by management fees and its exposure to U.S. TIPS.